AMR

Europe’s public-private Innovative Medicines Initiative (IMI) announced last week the launch of UNITE4TB—a $218 million, seven-year project to accelerate and improve the clinical evaluation of combinations of existing and novel drugs as treatment regimens for drug-resistant and drug-sensitive tuberculosis. UNITE4TB is the newest project of IMI’s AMR Accelerator.

The consortium—which involves 30 partners including academic institutions, GSK, J&J’s Janssen subsidiary, KNCV…

Mentions:

J&J last week launched a research center hosted at the London School of Hygiene & Tropical Medicine (LSHTM) that will focus on antimicrobial resistance (AMR) and next-generation TB drug regimens. The J&J Satellite Center for Global Health Discovery at LSHTM marks the first in a planned series of academic research centers, according to a company press release.

Each center will partner with academic institutions to focus on threats with high unmet need, including AMR,…

Mentions:

The Geneva-based Global Antibiotic Research and Development Partnership (GARDP) announced Tuesday that it has signed a memorandum of understanding (MOU) with the Clinton Health Access Initiative (CHAI) and Shionogi to accelerate LMIC access to the Osaka-based drugmaker’s antibiotic cefiderocol (Fetroja).

The collaboration will help introduce the drug—indicated for bacterial infections in patients with limited treatment options—into health systems and provide clinical guidance to…

Seres Therapeutics announced last week an agreement with Nestlé Health Science to jointly commercialize SER-109—the Massachusetts-based company’s investigational oral microbiome treatment for recurrent C. difficile infection—in the United States and Canada.

Under the deal, Seres will receive $175 million upfront in license payments, an additional $125 million upon U.S. FDA approval of the treatment, and up to $225 million in milestones. If approved, SER-109 would become the first U.S…

France’s bioMérieux and Specific Diagnostics announced Tuesday that bioMérieux will distribute the latter’s newly introduced REVEAL Rapid AST system in Europe.

The deal is a boost to the California-based CARB-X grantee’s antibiotic susceptibility testing (AST) system, designed to quickly detect the emitted volatile molecules that are the first sign of bacterial growth in the blood and to determine which antibiotic is most suited to kill the bacteria.

The press release noted…

San Diego-based Qpex Biopharma announced last week that it has begun a Phase 1 study of QPX9003, its next-generation intravenously administered synthetic polymyxin for infections caused by drug-resistant gram-negative pathogens (including Acinetobacter species and P. aeruginosa).

In other AMR news, the U.S. National Institutes of Health has awarded HelixBind $3.3 million to support testing of its RaPID/BSI diagnostic platform for sepsis-related bloodstream infections, the biotech…

The Access to Medicine (AtM) Foundation released a new report last week highlighting some biotechs that are finding novel ways to get badly needed antibiotics to patients in low- and middle-income countries despite notoriously difficult market conditions.

Drawing on “new data and discussions with stakeholders,” the report said that small- and medium-sized companies (SMEs) now account for 75% of all late-stage antimicrobials in the R&D pipeline, with many large companies having…

Boston University-led nonprofit CARB-X announced Tuesday that it will give Arizona-based Accelerate Diagnostics $578,000 (plus up to $2.1 million in milestones) to develop a rapid optical imaging diagnostic for sepsis and serious antibiotic-resistant bacterial infections.

In other antimicrobial resistance news, Boston’s Selux Diagnostics announced Tuesday an additional $14.6 million award from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to develop a rapid…

The Lancet Infectious Diseases published study results on Monday showing that the efficacy of the non-artemisinin-based triple-drug combination arterolane-piperaquine-mefloquine was noninferior to both arterolane-piperaquine and the artemisinin-based combination artemether-lumefantrine for treating uncomplicated P. falciparum malaria.

The study—funded by the Gates Foundation and Wellcome, among others—said the triple combination could “potentially be used to prevent or delay the…

Mentions:

CARB-X announced Tuesday that it will give Swiss biopharma BioVersys up to $4.3 million (plus up to $11 million in milestones) to develop new antibiotics to treat life-threatening infections caused by multidrug-resistant “ESKAPE” pathogens, including E. faecium, S. aureus, K. pneumoniae, A. baumannii, P. aeruginosa and Enterobacter species.

BioVersys’ novel class of pyrrolocytosine small molecules have exhibited “robust coverage” of all relevant Gram-negative pathogens as well as other…